Jia Liu
Research Subjects
Research Interests
Jia Liu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Zhe Wang
The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
2 shared publications - Bin Su
Anhui Center for Disease Control and Prevention, Hefei, China
1 shared publication - Chunhua Liu
Henan Center for Disease Control and Prevention, Zhengzhou, Henan China
1 shared publication Dingyong Sun
1 shared publication- Dingyong Sun
Henan Center for Disease Control and Prevention, Zhengzhou, Henan China
1 shared publication - Guoqing Sun
Henan Center for Disease Control and Prevention, Zhengzhou, Henan China
1 shared publication
Latest Publications
- Open Access
- 6 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Financial incentives framework for HIV treatment- Expansion of HIV digital vaccine (Preprint)
BACKGROUND Financial incentives can improve the compliance and health behaviors of patients. In recent years, financial incentives for HIV treatment have been continuously studied and practiced. OBJECTIVE This study aimed to provide a simple economic interpretation of the basic issues of financial incentives for HIV treatment and propose a financial incentives framework for HIV treatment. METHODS The concept of externality was used to analyze the importance of financial incentives for HIV treatment. HIV digital vaccine (HDV) strategy was used to concisely identify the beneficiary population and discuss the method of pay and feasibility. Based on these analyses, a framework to build a financial incentive path for the routine hospital visiting processes using blockchain and cryptocurrency was proposed. RESULTS Preventing HIV transmission is the main positive externality of HIV treatment that should be paid by the beneficiary population, that is, the voluntary users (vaccinees) of HDV who are at high risk of HIV infection. The framework is as follows: the HDV project owner develops a financial incentives Dapp and sets up a token account on the applicable blockchain. The users of the Dapp are the people with HIV in treatment. The tokens paid by vaccinees for HDV service are automatically deposited into the account in a specific proportion. The decision regarding the payment of the financial incentive is taken by the hospital. The evaluation is done automatically by the hospital information system following set computer programs after collecting the information generated during the routine visit and virus load test of the patient. CONCLUSIONS The framework makes the financial incentives of HIV treatment reasonable, precise, and efficient; forming a systematic ecology of HIV prevention and treatment, thereby help to reduce the social costs of HIV containment.
- 6 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessFinancial incentives framework for HIV treatment- Expansion of HIV digital vaccine (Preprint)
BACKGROUND Financial incentives can improve the compliance and health behaviors of patients. In recent years, financial incentives for HIV treatment have been continuously studied and practiced. OBJECTIVE This study aimed to provide a simple economic interpretation of the basic issues of financial incentives for HIV treatment and propose a financial incentives framework for HIV treatment. METHODS The concept of externality was used to analyze the importance of financial incentives for HIV treatment. HIV digital vaccine (HDV) strategy was used to concisely identify the beneficiary population and discuss the method of pay and feasibility. Based on these analyses, a framework to build a financial incentive path for the routine hospital visiting processes using blockchain and cryptocurrency was proposed. RESULTS Preventing HIV transmission is the main positive externality of HIV treatment that should be paid by the beneficiary population, that is, the voluntary users (vaccinees) of HDV who are at high risk of HIV infection. The framework is as follows: the HDV project owner develops a financial incentives Dapp and sets up a token account on the applicable blockchain. The users of the Dapp are the people with HIV in treatment. The tokens paid by vaccinees for HDV service are automatically deposited into the account in a specific proportion. The decision regarding the payment of the financial incentive is taken by the hospital. The evaluation is done automatically by the hospital information system following set computer programs after collecting the information generated during the routine visit and virus load test of the patient. CONCLUSIONS The framework makes the financial incentives of HIV treatment reasonable, precise, and efficient; forming a systematic ecology of HIV prevention and treatment, thereby help to reduce the social costs of HIV containment.
- Open Access
- 13 June 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (6) , e37133
HIV Digital Vaccine Strategy: Proposal for Applying Blockchain in Preventing the Spread of HIV
Background: The HIV epidemic imposes a heavy burden on societal development. Protection of susceptible populations is the most feasible method for eliminating the spread of HIV. In the absence of a biological vaccine, the definitive solution is enabling susceptible populations to recognize and avoid high-risk sexual behavior. Objective: The objective of this study is to use specific technologies and strategies to establish a system by which high-HIV-risk individuals can determine the HIV infection status of one another anonymously, conveniently, and credibly. Methods: This study proposes an HIV digital vaccine (HDV) strategy, a decentralized application (Dapp) based on blockchain for use by individuals with a high risk of HIV and accredited testing agencies (ATAs). Following testing, only the HIV-negative results (or linked information) are uploaded to the blockchain, which results in high-risk individuals being able to determine the HIV-negative status of each other anonymously, conveniently, and credibly. Results: Future work includes the following: (1) a survey of the willingness to use Dapps among high-HIV-risk populations, (2) a larger framework containing both HDV and people living with HIV (PLH) and discussing the influence of HDV on PLH and its possible solutions, and (3) coordinating with the blockchain development team, ATAs, community-based organizations, and third-party organizations to raise funds, develop the Dapp, formulate detailed plans, and publicize and promote it. The exact timeline for achieving these objectives cannot be determined at present. Conclusions: The HDV strategy may reduce the occurrence of high-risk sexual behavior and effectively protect susceptible populations; combined with current strategies, it is a promising solution to prevent the spread of HIV. The included concepts of decentralized surveillance and surveillance as intervention may spark a change in current infectious disease prevention and control modes to introduce beneficial innovations in public health systems globally.
- 13 June 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (6) , e37133
Open AccessHIV Digital Vaccine Strategy: Proposal for Applying Blockchain in Preventing the Spread of HIV
Background: The HIV epidemic imposes a heavy burden on societal development. Protection of susceptible populations is the most feasible method for eliminating the spread of HIV. In the absence of a biological vaccine, the definitive solution is enabling susceptible populations to recognize and avoid high-risk sexual behavior. Objective: The objective of this study is to use specific technologies and strategies to establish a system by which high-HIV-risk individuals can determine the HIV infection status of one another anonymously, conveniently, and credibly. Methods: This study proposes an HIV digital vaccine (HDV) strategy, a decentralized application (Dapp) based on blockchain for use by individuals with a high risk of HIV and accredited testing agencies (ATAs). Following testing, only the HIV-negative results (or linked information) are uploaded to the blockchain, which results in high-risk individuals being able to determine the HIV-negative status of each other anonymously, conveniently, and credibly. Results: Future work includes the following: (1) a survey of the willingness to use Dapps among high-HIV-risk populations, (2) a larger framework containing both HDV and people living with HIV (PLH) and discussing the influence of HDV on PLH and its possible solutions, and (3) coordinating with the blockchain development team, ATAs, community-based organizations, and third-party organizations to raise funds, develop the Dapp, formulate detailed plans, and publicize and promote it. The exact timeline for achieving these objectives cannot be determined at present. Conclusions: The HDV strategy may reduce the occurrence of high-risk sexual behavior and effectively protect susceptible populations; combined with current strategies, it is a promising solution to prevent the spread of HIV. The included concepts of decentralized surveillance and surveillance as intervention may spark a change in current infectious disease prevention and control modes to introduce beneficial innovations in public health systems globally.
- Open Access
- 8 February 2022
- Published by JMIR Publications Inc. in JMIR Preprints
HIV Digital Vaccine Strategy: Proposal for Applying Blockchain in Preventing the Spread of HIV (Preprint)
BACKGROUND The HIV epidemic imposes a heavy burden on societal development. Protection of susceptible populations is the most feasible method for eliminating the spread of HIV. In the absence of a biological vaccine, the definitive solution is enabling susceptible populations to recognize and avoid high-risk sexual behavior. OBJECTIVE The objective of this study is to use specific technologies and strategies to establish a system by which high-HIV-risk individuals can determine the HIV infection status of one another anonymously, conveniently, and credibly. METHODS This study proposes an HIV digital vaccine (HDV) strategy, a decentralized application (Dapp) based on blockchain for use by individuals with a high risk of HIV and accredited testing agencies (ATAs). Following testing, only the HIV-negative results (or linked information) are uploaded to the blockchain, which results in high-risk individuals being able to determine the HIV-negative status of each other anonymously, conveniently, and credibly. RESULTS Future work includes the following: (1) a survey of the willingness to use Dapps among high-HIV-risk populations, (2) a larger framework containing both HDV and people living with HIV (PLH) and discussing the influence of HDV on PLH and its possible solutions, and (3) coordinating with the blockchain development team, ATAs, community-based organizations, and third-party organizations to raise funds, develop the Dapp, formulate detailed plans, and publicize and promote it. The exact timeline for achieving these objectives cannot be determined at present. CONCLUSIONS The HDV strategy may reduce the occurrence of high-risk sexual behavior and effectively protect susceptible populations; combined with current strategies, it is a promising solution to prevent the spread of HIV. The included concepts of decentralized surveillance and surveillance as intervention may spark a change in current infectious disease prevention and control modes to introduce beneficial innovations in public health systems globally. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/37133
- 8 February 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessHIV Digital Vaccine Strategy: Proposal for Applying Blockchain in Preventing the Spread of HIV (Preprint)
BACKGROUND The HIV epidemic imposes a heavy burden on societal development. Protection of susceptible populations is the most feasible method for eliminating the spread of HIV. In the absence of a biological vaccine, the definitive solution is enabling susceptible populations to recognize and avoid high-risk sexual behavior. OBJECTIVE The objective of this study is to use specific technologies and strategies to establish a system by which high-HIV-risk individuals can determine the HIV infection status of one another anonymously, conveniently, and credibly. METHODS This study proposes an HIV digital vaccine (HDV) strategy, a decentralized application (Dapp) based on blockchain for use by individuals with a high risk of HIV and accredited testing agencies (ATAs). Following testing, only the HIV-negative results (or linked information) are uploaded to the blockchain, which results in high-risk individuals being able to determine the HIV-negative status of each other anonymously, conveniently, and credibly. RESULTS Future work includes the following: (1) a survey of the willingness to use Dapps among high-HIV-risk populations, (2) a larger framework containing both HDV and people living with HIV (PLH) and discussing the influence of HDV on PLH and its possible solutions, and (3) coordinating with the blockchain development team, ATAs, community-based organizations, and third-party organizations to raise funds, develop the Dapp, formulate detailed plans, and publicize and promote it. The exact timeline for achieving these objectives cannot be determined at present. CONCLUSIONS The HDV strategy may reduce the occurrence of high-risk sexual behavior and effectively protect susceptible populations; combined with current strategies, it is a promising solution to prevent the spread of HIV. The included concepts of decentralized surveillance and surveillance as intervention may spark a change in current infectious disease prevention and control modes to introduce beneficial innovations in public health systems globally. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/37133
- Open Access
- 18 February 2019
- Published by JMIR Publications Inc. in JMIR Preprints
HIV digital vaccine strategy: An application of blockchain technology in preventing the spread of HIV (Preprint)
UNSTRUCTURED The HIV epidemic imposes a heavy burden on societal development. Presently, the protection of susceptible populations is the most feasible method for eliminating the spread of HIV. Governments and other relevant industries are actively attempting to solve the problem. In view of the unavailability of biological vaccines, the best measures that can currently be applied are identification of HIV-infected persons and provision of treatment and behavioral intervention. This paper proposes a HIV digital vaccine strategy based on blockchain technology. In the proposed strategy, a decentralized surveillance network is jointly constructed using HIV high-risk individuals as application nodes and accredited testing agencies as authentication nodes. Following testing at the authentication nodes, the results are uploaded to the blockchain, which results in HIV high-risk individuals being able to determine the HIV infection status of each other in a convenient, anonymous, and credible manner. This reduces the occurrence of high-risk sexual behavior and effectively protects susceptible populations. The proposed strategy is a promising solution to prevent the spread of HIV. The performance of the decentralized surveillance network may lead to the restructuring of current government-funded infectious disease prevention and control modes that are centered on centers for disease control and prevention and hospitals to introduce revolutionary changes in public health systems globally.
- 18 February 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessHIV digital vaccine strategy: An application of blockchain technology in preventing the spread of HIV (Preprint)
UNSTRUCTURED The HIV epidemic imposes a heavy burden on societal development. Presently, the protection of susceptible populations is the most feasible method for eliminating the spread of HIV. Governments and other relevant industries are actively attempting to solve the problem. In view of the unavailability of biological vaccines, the best measures that can currently be applied are identification of HIV-infected persons and provision of treatment and behavioral intervention. This paper proposes a HIV digital vaccine strategy based on blockchain technology. In the proposed strategy, a decentralized surveillance network is jointly constructed using HIV high-risk individuals as application nodes and accredited testing agencies as authentication nodes. Following testing at the authentication nodes, the results are uploaded to the blockchain, which results in HIV high-risk individuals being able to determine the HIV infection status of each other in a convenient, anonymous, and credible manner. This reduces the occurrence of high-risk sexual behavior and effectively protects susceptible populations. The proposed strategy is a promising solution to prevent the spread of HIV. The performance of the decentralized surveillance network may lead to the restructuring of current government-funded infectious disease prevention and control modes that are centered on centers for disease control and prevention and hospitals to introduce revolutionary changes in public health systems globally.
- Open Access
- 26 September 2018
- Published by JMIR Publications Inc. in JMIR Preprints
HIV digital vaccine strategy: An application of blockchain technology in preventing the spread of HIV (Preprint)
UNSTRUCTURED The HIV epidemic poses a heavy burden on societal development. Presently, the protection of susceptible populations is the most feasible method for eliminating the spread of HIV. The government and other relevant industries always attempt at solving the problem, in view of the unavailability of biological vaccines, no better measures can take except identify HIV-infected persons, provide treatment and behavioral intervention. This study proposes a HIV digital vaccine strategy. Based on blockchain technology, a decentralized surveillance network has been jointly constructed using HIV high-risk individuals as application nodes and accredited testing agencies as authentication nodes. When testing accomplished at authentication nodes, the results uploaded to the blockchain, thus HIV high-risk populations can determine the HIV infection status of one another in a convenient, anonymous, and credible manner, thereby reducing the occurrences of high-risk sexual behavior and effectively protecting susceptible populations. This is a promising solution to prevent the spread of HIV. The performance of decentralized surveillance network may lead to the restructuring of current government-funded infectious disease prevention and control modes that are centered on centers for disease control and prevention and hospitals to introduce revolutionary changes in public health systems globally.
- 26 September 2018
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessHIV digital vaccine strategy: An application of blockchain technology in preventing the spread of HIV (Preprint)
UNSTRUCTURED The HIV epidemic poses a heavy burden on societal development. Presently, the protection of susceptible populations is the most feasible method for eliminating the spread of HIV. The government and other relevant industries always attempt at solving the problem, in view of the unavailability of biological vaccines, no better measures can take except identify HIV-infected persons, provide treatment and behavioral intervention. This study proposes a HIV digital vaccine strategy. Based on blockchain technology, a decentralized surveillance network has been jointly constructed using HIV high-risk individuals as application nodes and accredited testing agencies as authentication nodes. When testing accomplished at authentication nodes, the results uploaded to the blockchain, thus HIV high-risk populations can determine the HIV infection status of one another in a convenient, anonymous, and credible manner, thereby reducing the occurrences of high-risk sexual behavior and effectively protecting susceptible populations. This is a promising solution to prevent the spread of HIV. The performance of decentralized surveillance network may lead to the restructuring of current government-funded infectious disease prevention and control modes that are centered on centers for disease control and prevention and hospitals to introduce revolutionary changes in public health systems globally.
- Open Access
- 27 June 2015
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 12 (1) , 22
Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010–2011
In Henan, China, first-line antiretroviral treatment (ART) was implemented early in a large number of treatment-experienced patients who were more likely to have a drug resistance. Therefore, we investigated the human immunodeficiency virus (HIV)-1 drug resistance profiles among patients in Henan who experienced virological failure to ART. A cross-sectional survey was administered in 10 major epidemic cities from May 2010 to October 2011. Adult patients who experienced virological failure (virus load ≥1,000 copies/mL) with >1 year of first-line antiretroviral treatment consented to provide blood for genotype resistance testing. The clinical and demographic data were obtained from the patients’ medical records. Logistic regression analysis was performed to determine the factors associated with ≥1 significant drug resistance mutation. We included 3,235 patients with integral information and valid genotypic resistance data. The city, age, CD4 counts, virus load, treatment duration, and World Health Organization stage were associated with drug resistance, and 64.76% of patients acquired drug resistance. The nucleoside reverse transcriptase inhibitor (NRTI), non-(N)NRTI, and protease inhibitor resistance mutations were found in 50.26, 63.12, and 1.30% of subjects, respectively. Thymidine analogue mutations, NNRTI and even multidrug resistance complex were quite common in this patient cohort. Multiple and complex patterns of HIV-1 drug resistance mutations were identified among individuals who experienced virological failure to first-line ART in Henan, China during 2010–2011. Therefore, timely virological monitoring, therapy adjustments, and more varieties of drugs and individualized treatment should be immediately considered in this patient population.
- 27 June 2015
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 12 (1) , 22
Open AccessPopulation-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010–2011
In Henan, China, first-line antiretroviral treatment (ART) was implemented early in a large number of treatment-experienced patients who were more likely to have a drug resistance. Therefore, we investigated the human immunodeficiency virus (HIV)-1 drug resistance profiles among patients in Henan who experienced virological failure to ART. A cross-sectional survey was administered in 10 major epidemic cities from May 2010 to October 2011. Adult patients who experienced virological failure (virus load ≥1,000 copies/mL) with >1 year of first-line antiretroviral treatment consented to provide blood for genotype resistance testing. The clinical and demographic data were obtained from the patients’ medical records. Logistic regression analysis was performed to determine the factors associated with ≥1 significant drug resistance mutation. We included 3,235 patients with integral information and valid genotypic resistance data. The city, age, CD4 counts, virus load, treatment duration, and World Health Organization stage were associated with drug resistance, and 64.76% of patients acquired drug resistance. The nucleoside reverse transcriptase inhibitor (NRTI), non-(N)NRTI, and protease inhibitor resistance mutations were found in 50.26, 63.12, and 1.30% of subjects, respectively. Thymidine analogue mutations, NNRTI and even multidrug resistance complex were quite common in this patient cohort. Multiple and complex patterns of HIV-1 drug resistance mutations were identified among individuals who experienced virological failure to first-line ART in Henan, China during 2010–2011. Therefore, timely virological monitoring, therapy adjustments, and more varieties of drugs and individualized treatment should be immediately considered in this patient population.
- Open Access
- 21 November 2014
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 11 (1) , 36
The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy
We built a cohort study of HIV patients taking long-term first-line Antiretroviral Therapy in 2003. In this assay, we focused on the development of primary drug resistance mutations against Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), K103N, Y181C and G190A. The cohort study was built in Henan province, China. We used Single Genome Amplification (SGA) to analyze the frequency of K103N, Y181C and G190A in serial plasma samples of three individual patients. We also performed standard genotype HIV drug resistance assay in 204 patients of this cohort study to analyze the frequency of these mutations. In the SGA sequences, the K103N decreased and vanished, while the frequency of Y181C and G190A increased in individual patient receiving long-term Antiretroviral Therapy (ART). In the sequences of standard genotype HIV drug resistance assay, the frequency of K103N, Y181C and G190A had the similar pattern with that in SGA sequences. Among these patients, the viral suppression were still sufficient after receiving ART for 72 months, and 78.6% (160/204) patients could have their CD4 count over than 200cells/ul. In some patients, first-line ART had the possibility to provide sufficient treatment effect for over than 72 months, but in long-term treatment, the dominant NNRTI drug resistance mutation K103N could reduced, while the proportion of variants with mutation Y181C or G190A may increased. This result was not similar with that in vitro study, which state that variant with K103N or Y181C had an equal viral fitness with wild type.
- 21 November 2014
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 11 (1) , 36
Open AccessThe development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy
We built a cohort study of HIV patients taking long-term first-line Antiretroviral Therapy in 2003. In this assay, we focused on the development of primary drug resistance mutations against Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), K103N, Y181C and G190A. The cohort study was built in Henan province, China. We used Single Genome Amplification (SGA) to analyze the frequency of K103N, Y181C and G190A in serial plasma samples of three individual patients. We also performed standard genotype HIV drug resistance assay in 204 patients of this cohort study to analyze the frequency of these mutations. In the SGA sequences, the K103N decreased and vanished, while the frequency of Y181C and G190A increased in individual patient receiving long-term Antiretroviral Therapy (ART). In the sequences of standard genotype HIV drug resistance assay, the frequency of K103N, Y181C and G190A had the similar pattern with that in SGA sequences. Among these patients, the viral suppression were still sufficient after receiving ART for 72 months, and 78.6% (160/204) patients could have their CD4 count over than 200cells/ul. In some patients, first-line ART had the possibility to provide sufficient treatment effect for over than 72 months, but in long-term treatment, the dominant NNRTI drug resistance mutation K103N could reduced, while the proportion of variants with mutation Y181C or G190A may increased. This result was not similar with that in vitro study, which state that variant with K103N or Y181C had an equal viral fitness with wild type.